← Leaderboards
Amy Fulton
University Of Maryland Baltimore
$3,639,782
Attributed
$3,639,782
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $323.3K · FY2005–20$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$3,639,782 · 3
VA$0 · 1
By mechanism
R01$3,347,097 · 2
P30$292,685 · 1
I01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Priscilla A. Furth$6,008,619
- Linda H Malkas$5,757,557
- Antonino Passaniti$1,328,420
- Cedric X Yu$3,773,246
- Konstantin G Birukov$17,515,935
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsNeoplasm MetastasisTumorMalignant Breast NeoplasmReceptorProstaglandin E ReceptorNovel StrategiesImmunePreventSolidMalignant - DescriptorTumor GrowthCyclooxygenase 2LigandsMammary NeoplasmsNatural Killer CellsDinoprostoneMediatingG-Protein-Coupled ReceptorsApoptosisBreastHormonesBinding (Molecular Function)Cyclooxygenase Inhibitors
Grant awards (31)
Targeting the COX-2 Pathway to Reduce Breast Cancer Mortality$0
I01 · FY2020 · VA · contact PI
Hormone Responsive Cancers (HRC)$38,032
P30 · FY2019 · CA · contact PI
Hormone Responsive Cancers (HRC)$38,032
P30 · FY2018 · CA · contact PI
Hormone Responsive Cancers (HRC)$34,975
P30 · FY2018 · CA · contact PI
Hormone Responsive Cancers (HRC)$11,110
P30 · FY2018 · CA · contact PI
Hormone Responsive Cancers (HRC)$6,943
P30 · FY2018 · CA · contact PI
Targeting the COX-2 Pathway to Reduce Breast Cancer Mortality$0
I01 · FY2018 · VA · contact PI
Hormone Responsive Cancers (HRC)$38,051
P30 · FY2017 · CA · contact PI
Targeting the COX-2 Pathway to Reduce Breast Cancer Mortality$0
I01 · FY2017 · VA · contact PI
Hormone Responsive Cancers (HRC)$125,542
P30 · FY2016 · CA · contact PI
Targeting the COX-2 Pathway to Reduce Breast Cancer Mortality$0
I01 · FY2016 · VA · contact PI
Targeting the COX-2 Pathway to Reduce Breast Cancer Mortality$0
I01 · FY2015 · VA · contact PI
Targeting the COX-2 Pathway to Reduce Breast Cancer Mortality$0
I01 · FY2012 · VA · contact PI
Cyclooxygenase Modulators of Immune Function in Breast Cancer$266,937
R01 · FY2011 · CA · contact PI
Cyclooxygenase Modulators of Immune Function in Breast Cancer$12,987
R01 · FY2011 · CA · contact PI
Targeting the COX-2 Pathway to Reduce Breast Cancer Mortality$0
I01 · FY2011 · VA · contact PI
Targeting the COX-2 Pathway to Reduce Breast Cancer Mortality$0
I01 · FY2011 · VA · contact PI
Cyclooxygenase Modulators of Immune Function in Breast Cancer$277,161
R01 · FY2010 · CA · contact PI
Cyclooxygenase Modulators of Immune Function in Breast Cancer$46,170
R01 · FY2010 · CA · contact PI
Cyclooxygenase Modulators of Immune Function in Breast Cancer$278,935
R01 · FY2009 · CA · contact PI
Cyclooxygenase Modulators of Immune Function in Breast Cancer$32,000
R01 · FY2009 · CA · contact PI
Targeting the COX-2 Pathway to Reduce Breast Cancer Mortality$0
I01 · FY2009 · VA · contact PI
Cyclooxygenase Modulators of Immune Function in Breast Cancer$278,333
R01 · FY2008 · CA · contact PI
Cyclooxygenase Modulators of Immune Function in Breast Cancer$278,320
R01 · FY2007 · CA · contact PI
Interleukin 10 and Breast Cancer Therapy$258,118
R01 · FY2006 · CA · contact PI
Interleukin 10 and Breast Cancer Therapy$264,330
R01 · FY2005 · CA
Interleukin 10 and Breast Cancer Therapy$264,330
R01 · FY2004 · CA
Interleukin 10 and Breast Cancer Therapy$264,330
R01 · FY2003 · CA
Interleukin 10 and Breast Cancer Therapy$264,330
R01 · FY2002 · CA
INTERLEUKIN 10 AND BREAST CANCER THERAPY$284,553
R01 · FY2001 · CA
INTERLEUKIN 10 AND BREAST CANCER THERAPY$276,263
R01 · FY2000 · CA